Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of participants treated with letetresgene autoleucel or other ADP adoptive cell therapies
NL-OMON58741Phase 1Not yet recruiting
- Sponsor
- US WorldMeds
- Start
- Nov 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of letetresgene autoleucel in multiple myeloma (MM), synovial sarcoma (SS), non-small cell lung cancer (NSCLC) and 1 more, sponsored by US WorldMeds. Primary endpoints: New malignancies, Neurologic disorders and 4 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
letetresgene autoleucel
03
Conditions
multiple myeloma (MM)synovial sarcoma (SS)non-small cell lung cancer (NSCLC)Myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on NL-OMON58741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58741.